Neurology Labs - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

Neurology Labs

Description:

Title: Laboratory Medicine Lecture 1 Author: Brian Last modified by: Brian Document presentation format: Letter Paper (8.5x11 in) Company: Brenda Beckett – PowerPoint PPT presentation

Number of Views:69
Avg rating:3.0/5.0
Slides: 19
Provided by: Bria4345
Category:

less

Transcript and Presenter's Notes

Title: Neurology Labs


1
Neurology Labs
  • Brenda Beckett, PA-C
  • Clinical Assessment II

2
Cerebrospinal Fluid (CSF)
  • Clear fluid that occupies subarachnoid space and
    ventricles
  • Produced in the choroid plexus
  • Obtained by lumbar puncture (L3-L4)
  • Usually clear, colorless, acellular, sterile
  • Traumatic tap

3
Cerebrospinal Fluid
  • WBC, RBC
  • Protein
  • Glucose
  • Culture
  • Other tests
  • (see table p 307-313 Wallach)

4
Multiple Sclerosis
  • CSF IgG, nonspecific marker (also elevated in
    neurosyphilis, Guillan-Barre, head trauma,
    leukemia, etc)
  • Measure CSF and serum IgG and albumin. (to
    determine increased production in CNS vs crossing
    bb barrier)

5
Multiple Sclerosis
  • CSF IgG Index. Compares ratio of CSF IgG albumin
    to serum IgGalbumin ratio.

6
Multiple Sclerosis
  • Oligoclonal proteins (or bands)- shows discrete
    bands on electrophoresis.
  • Perform on CSF and serum
  • MS will show CSF, neg serum
  • myelin basic protein (MBP) may be observed during
    active demyelinization.
  • Perform on CSF
  • Used to monitor therapy

7
Myasthenia Gravis
  • Acetylchoine receptor (AChR) antibodies (3
    different Abbinding, blocking, modulating).
  • Positive in gt85 of pts with generalized sx, 50
    of pts with occular sx.
  • Also check thyroid function. At risk for other
    autoimmune diseases.

8
Therapeutic Drug Monitoring (TDM)
  • Measures the level of some drugs as a way to
    determine the most effective dose or to avoid
    toxicity.
  • Most drugs do not need to be monitored this way.
  • Monitor drugs that have narrow therapeutic
    window, toxic side effects.

9
TDM
  • Therapeutic range Concentration where the drug
    has been shown to be efficacious without causing
    toxic effects in most people.

10
Drug Category Drugs in that Category Treatment Use
Cardiac drugs          Digoxin, quinidine, procainamide, N-acetyl-procainamide (a metabolite of procainamide) CHF, angina, arrhythmias
Antibiotics Aminoglycosides (gentamicin, tobramycin, amikacin),Vancomycin, Chloramphenicol Infections with bacteria that are resistant to less toxic antibiotics
11
Drug Category Drugs in that Category Treatment Use
Antiepileptics Phenobarbital, phenytoin, valproic acid, carbamazepine, ethosuximide, gabapentin, lamotrigine Epilepsy, prevention of seizures
Bronchodilators Theophylline, caffeine Asthma, COPD, neonatal apnea
Immuno-suppressants Cyclosporine, tacrolimus, sirolimus, mycophenolate mofetile Prevent rejection of transplanted organs
12
Drug Category Drugs in that Category Treatment Use
Anti-cancer drugs Methotrexate Cancers, rheumatoid arthritis, non-hodgkin's lymphomas, osteosarcoma, psoriasis
Psychiatric drugs Lithium, desipramine, some antidepressants (imipramine, amitriptyline, nortriptyline, doxepin) bipolar disorder, depression
13
TDM
  • Specimen collection time in relation to dose is
    important.
  • Sampling time is most frequent error
  • Trough vs peak
  • Most are drawn as trough, except some antibiotics
  • Steady state
  • After multiple doses

14
Case Study
  • History and presentation
  • 33yo female, admitted for sudden, bilat loss of
    vision. 1yr ago, had difficulty walking, improved
    w/i 2wks. Occ tingling and electrical sensation
    down her back with flexed neck. Occ difficulty
    expressing herself verbally.

15
Case Study
  • Physical exam
  • AO, mild distress, speech normal
  • No light perception bilat, EOMI. No nystagmus,
    Pupils sluggishly reactive to light.
  • Paraparesis with spacicity and dissociated
    sensory loss in LE.
  • Sensory level at T7.
  • Brisk patellar DTRs and bilat Babinskis
  • Remainder of PE unremarkable

16
Case Study
  • What is your differential diagnosis?
  • -
  • -
  • What lab testing do you want to perform?
  • -

17
Case Study
  • What additional CSF test(s) would you like to
    order?
  • -
  • Results
  • -

18
Case Study
  • What is your diagnosis?
  • -
Write a Comment
User Comments (0)
About PowerShow.com